randomized controlled clinical

Related by string. * Randomized . randomizing . randomizer : randomized controlled trial . randomized controlled trials . randomized placebo controlled / controlling . controller . Controller : obtaining controlled substance . placebo controlled clinical trials / clinicals . CLINICAL : Phase III clinical trials . Phase III clinical * randomized controlled clinical trials *

Related by context. All words. (Click for frequent words.) 78 randomized clinical 77 prospective randomized controlled 75 randomized controlled 74 multicenter clinical 74 prospective randomized 72 placebo controlled clinical 72 multicenter randomized clinical 72 multicentre randomized 71 double blinded randomized 71 randomized Phase III 70 multicenter randomized controlled 70 prospective multicenter 70 multicenter 70 Phase III randomized 70 randomized multicenter trial 69 multicenter randomized 69 randomized placebo controlled 69 randomized controlled trial 69 prospective observational 69 ONTARGET 69 prospective multicenter randomized 68 nonrandomized 68 RE LY ® 68 placebo controlled randomized 68 multicentre 68 placebo controlled 68 randomized blinded 68 SPIRIT IV 67 multicenter randomized placebo controlled 67 multicenter prospective 67 randomized multicenter 67 placebo controlled Phase III 67 multicenter study 67 TAXUS ATLAS 67 Phase IIIb clinical 67 SPIRIT III 67 multicenter randomized double 67 randomized Phase IIb 66 Randomized controlled 66 phase IIb clinical 66 NO# [002] 66 EVEREST II 66 CYPHER R Sirolimus eluting 66 SPIRIT FIRST 66 blind randomized 66 multicenter placebo controlled 65 ExTRACT TIMI 65 Carotid Revascularization Endarterectomy vs. 65 blinded randomized 65 multicenter trials 65 active comparator 65 ABSORB trial 65 prospective randomized multicenter 65 Phase Ib clinical 65 double blind placebo 65 double blinded placebo 65 blind randomized placebo 65 Phase 2a clinical 65 Prostate Lung Colorectal 65 phase IIb 65 Phase 2b study 65 PFO migraine 65 masked placebo controlled 65 Clinical Antipsychotic Trials 65 RE LY 65 placebo controlled Phase 64 phase IIa clinical 64 multicentre randomized controlled 64 phase IIIb 64 multicenter Phase II 64 Phase IIIb 64 multicentre randomized double 64 randomized controlled clinical trials 64 dose escalation clinical 64 randomized clinical trials 64 CYPHER ® Sirolimus eluting 64 blinded randomized controlled 64 phase IIa 64 Intervention Effectiveness 64 Sorafenib HCC Assessment 64 ENDEAVOR IV 64 blind randomized controlled 64 Phase IIIb study 64 PRECISE 64 DAPT 64 Prostate Cancer Prevention 64 Phase IIB 64 AVADO 64 EchoCRT 63 ToGA 63 ADMIRE HF 63 randomized 63 Stenting Trial CREST 63 CARE HF 63 placebo controlled studies 63 BRIM3 63 randomized double 63 blinded placebo controlled 63 subanalysis 63 NEVO RES 63 dose escalation Phase 63 controlled multicenter 63 prospective nonrandomized 63 HPTN 63 ASTEROID 63 multicenter Phase 63 label multicenter 63 REALITY Trial 63 trials RCTs 63 Ovarian PLCO Cancer 63 Randomized Evaluation 63 placebo controlled trials 63 phase Ib 63 confirmatory clinical 63 MADIT II 62 ENESTnd 62 dose escalation trial 62 ADVANCE PD 62 viral kinetic 62 landmark ATHENA 62 AVERROES 62 IMPROVE HF 62 Screening Trial 62 TMC# C# 62 TG MV 62 randomized controlled multicenter 62 Phase III VISTA 62 Prospective Randomized 62 phase III ACCLAIM 62 substudy 62 blinded randomized placebo controlled 62 clinical trial 62 PreCISe 62 Betaferon ® 62 Ovarian Cancer Screening 62 multicenter multinational 62 PRECiSE 62 randomized trials 62 BRIM2 62 Phase Ib II 62 AIM HIGH 62 analgesic efficacy 62 NATRECOR ® 62 TAXUS VI 62 Randomised 62 VADT 61 carotid artery stenting 61 PROMUS Element Stent 61 BARI 2D 61 Phase IIb III 61 registrational Phase 61 HORIZONS AMI trial 61 Edge STudy 61 noninferiority 61 randomized multicenter Phase III 61 HCV SPRINT 61 randomized controlled trials 61 NSABP B 61 OLYMPIA registry 61 Phase 2b clinical 61 Multicenter 61 ENDEAVOR III 61 prospective randomized placebo 61 multicentre study 61 retrospective observational study 61 LUX Lung 61 ACUITY trial 61 ACCORD Lipid 61 Intervention Effectiveness CATIE 61 BOLDER II 61 randomized controlled Phase 61 Phase 1b clinical 61 EURIDIS 61 Val HeFT 61 ROCKET AF 61 HORIZONS AMI 61 paclitaxel eluting stents 61 MIST II 61 pharmacokinetic PK 61 MADIT 61 CALGB 61 Phase #/#a 61 riociguat 61 observational study 61 CUSTOM II 61 Edwards SAPIEN valve 61 Phase 1a 61 multicenter phase 61 CUSTOM III 61 everolimus eluting stents 61 longitudinal cohort study 61 pivotal bioequivalence 61 carotid stenting 61 CAMMS# 60 PERSEUS 60 STICH trial 60 Acute Myocardial Infarction 60 nab paclitaxel 60 subgroup analyzes 60 phase IIb trial 60 PRIMO CABG 60 SYNTAX trial 60 blind multicenter 60 PRE SURGE 60 CYPHER ® Stent 60 multicenter Phase III 60 phase Ib clinical 60 Phase III clinical 60 VITAL Trial 60 GEM OS1 60 label dose escalation 60 SYNTAX 60 Rosuvastatin 60 Coronary Stent 60 thorough QT 60 STRIDE PD 60 ASCEND HF 60 phase IIb study 60 carotid artery stenting CAS 60 Phase #b/#a clinical 60 RSD# oral 60 retrospective cohort study 60 elective PCI 60 blind placebo controlled 60 Cardiac Allograft Rejection 60 AIR CF2 60 Phase III placebo controlled 60 Phase III randomized controlled 60 PERSEUS clinical program 60 superficial bladder cancer 60 teriflunomide 60 randomized multicentre 60 TAXUS IV 60 CHAMPION PCI 60 everolimus eluting stent 60 PRoFESS 60 ACTIVE W 60 NEVO 60 MADIT CRT 59 ADAGIO study 59 Phase 1b trial 59 RIO Lipids 59 Prostate AdenoCarcinoma Treatment 59 AIR CF1 59 ATTRACT 59 BR.# 59 BOLDER 59 phase 2a 59 fosbretabulin 59 ABSORB clinical 59 CLORETAZINE TM VNP#M 59 Intervention Trial GAIT 59 assessing T DM1 59 pharmacodynamic profile 59 recurrent malignant glioma 59 EDEMA3 59 PREVENT IV 59 Phase IIb clinical 59 non inferiority 59 ENDEAVOR II 59 dose dose escalation 59 pharmacokinetics PK 59 relapsed MM 59 MERLIN TIMI 59 recurrent GBM 59 SCD HeFT 59 NCT# ClinicalTrials.gov 59 IMPROVE IT 59 HeFT 59 Glucosamine Chondroitin Arthritis 59 relapsing multiple sclerosis 59 MEND CABG 59 Long Lesion 59 ACRIN 59 prospectively randomized 59 randomized Phase 59 Phase 2a trial 59 prospective multicentre 59 oral rivaroxaban 59 Digital Mammographic Imaging 59 ongoing Phase 1b 59 CLARITY TIMI 59 Acute Ischemic Stroke 59 European Sepsis Trial 59 Heart Failure Trial 59 pharmacodynamic effects 59 TAXUS Liberte Stent 59 Phase Ib study 59 Traficet EN 59 Randomized 59 Phase 2b kidney transplant 59 HCV RESPOND 2 59 Phase #b/#a 59 BCIRG 59 TRANSFORMS 59 ANCHOR trial 59 NCCTG 59 oral FTY# 59 pertuzumab 59 Prospective Randomized Trial 59 BRAF inhibitor 59 carotid endarterectomy CEA 59 CURRENT OASIS 7 59 placebo controlled clinical trials 59 sirolimus eluting stents 59 EORTC 58 treatment naive genotype 58 neoadjuvant 58 Pivotal Trial 58 DAPT Study 58 CIMZIA TM certolizumab pegol 58 ALLHAT 58 pharmacodynamics PD 58 Endeavor drug eluting 58 crizotinib PF # 58 evaluating Actimmune 58 VESTASYNC 58 Prospective Multicenter 58 SABCS 58 ritonavir boosted 58 DASISION 58 Phase 1a clinical 58 Outpatient Setting 58 ENDEAVOR clinical 58 biologic therapy 58 dose escalation study 58 retrospective cohort 58 MADIT CRT trial 58 Augment Injectable 58 National Emphysema Treatment 58 CYPHER R Stent 58 LUMINATE 58 Phase 1b 58 Spine Patient Outcomes 58 relapsing remitting MS RRMS 58 randomized Phase 2b 58 COMFORT II 58 Sequenced Treatment Alternatives 58 Phase III 58 galiximab 58 APPRAISE 58 Myocardial Infarction Study 58 bioabsorbable stent 58 Endovascular Valve Edge 58 Pivotal Clinical Trial 58 ACCOMPLISH 58 prospective multicenter study 58 unblinding 58 Phase Ib IIa clinical 58 recurrent glioblastoma multiforme 58 tanespimycin 58 ascending dose 58 Phase III pivotal 58 Phase IIb trial 58 Placebo controlled 58 ALTTO 58 evaluating tivozanib 58 APEX PD 58 placebo controlled multicenter 58 GAMMAGARD 58 ONTARGET R 58 TRITON TIMI 58 oral ridaforolimus 58 NSABP 58 RRMS patients 58 CLARITY study 58 multicentric 58 GORE VIABAHN Endoprosthesis 58 CLL8 58 safety tolerability pharmacokinetic 58 metastatic HRPC 58 Phase IIa clinical 58 Platelet Inhibition 58 Phase Ib 58 AIR CF3 58 clinical pharmacology studies 58 label multicenter Phase 58 HF ACTION 58 ECASS 58 pivotal Phase III 58 prospectively defined 58 Phase IIa trial 58 sunitinib malate 58 ABSORB 58 Randomized Clinical Trial 58 Randomized Study 58 Randomized Phase 58 viral kinetics 58 daily Infergen 58 TEMSO 58 Phase Ia 58 preclinical efficacy 58 AIR2 Trial 57 angiotensin receptor blocker ARB 57 OncoVEX GM CSF 57 PRESEPT 57 mg administered orally 57 Degarelix 57 single ascending dose 57 sulodexide 57 sorafenib Nexavar 57 SWOG 57 transcatheter aortic valve implantation 57 Phase III HEAT 57 APTIVUS 57 Endarterectomy 57 Randomized Phase II 57 Phase IIa 57 Stenting Trial 57 MitraClip device 57 Phase 2a 57 TAXUS TM 57 dosing cohorts 57 multicentre prospective 57 pralatrexate injection 57 Sirolimus eluting Coronary Stent 57 CAPRISA 57 AVOREN 57 Pemetrexed 57 budesonide foam 57 prospective cohort 57 HuMax EGFr 57 observational cohort study 57 International Verapamil SR 57 ELCAP 57 CALGB # [002] 57 GOUT 57 Clinical Outcomes Utilizing Revascularization 57 MAGE A3 ASCI 57 CATIE AD 57 CYPHER Stent 57 placebo controlled dose escalation 57 chemoradiotherapy 57 Trial NLST 57 randomized crossover 57 ILLUMINATE 57 ATACAND 57 Phase III psoriasis 57 PROactive study 57 meta analysis 57 tolerability pharmacokinetics 57 PARTNER Trial 57 TAXUS V 57 prospective observational cohort 57 Rheos System 57 trabectedin 57 pharmacokinetic PK study 57 fallopian tube cancers 57 MGd 57 EmbraceAC 57 GISSI HF 57 ASSERT trial 57 Pivotal Phase 57 NEVO ™ 57 MTWA testing 57 icatibant 57 Percutaneous Coronary Intervention 57 dose escalation 57 evaluable subjects 57 delafloxacin 57 Lung Screening 57 Microplasmin 57 pharmacokinetic characteristics 57 secondary efficacy endpoints 57 Phase Ib IIa 57 PFO closure 57 acute PAO 57 evaluating REVLIMID 57 Azedra 57 SUCCEED trial 57 dose escalation phase 57 Phase Ib clinical trials 57 RTOG 57 randomized blinded placebo 57 Amrubicin 57 Phase #/#a clinical 57 KRAS mutations occur 57 paclitaxel eluting stent 57 EUS FNA 57 Phase III Pivotal 57 opioid induced bowel dysfunction 57 Multicenter Randomized 57 RECORD1 57 RCTs 57 Phase 2b trial 57 Raloxifene Evaluation MORE 57 BETAS 57 dosage regimens 57 ALSYMPCA 57 EOquin TM 57 rFVIIa 57 anti arrhythmic drug 57 PLCO 57 Phase III Psoriasis 57 AERAS-#/Crucell Ad# 56 ZACTIMA 56 MIVI III 56 oral deforolimus 56 CHARM Added 56 Phase III Clinical Trial 56 Randomized Double blind 56 Multicenter Automatic Defibrillator Implantation 56 ABCSG 56 Combo Stent 56 axitinib 56 HIF PH inhibitors 56 Coronary Artery Bypass Graft 56 sirolimus eluting stent 56 NP2 Enkephalin 56 ACTEMRA 56 CHAMPION PLATFORM 56 tiotropium 56 Protelos 56 Aggressive Reduction 56 efficacy tolerability 56 pharmacokinetic studies 56 Truvada tablets 56 bosentan 56 CIMZIA ™ 56 ACCEDE 56 RE MODEL 56 glatiramer acetate 56 HOPE TOO 56 NICE SUGAR 56 Phase III metastatic melanoma 56 Elagolix 56 prucalopride 56 PRIMO CABG2 56 pain palliation 56 carotid stents 56 Initiated Phase 56 eptifibatide 56 Ophena TM 56 pharmacodynamic PD 56 tolvaptan 56 refractory CLL 56 EDEMA4 56 Aggressive Drug Evaluation 56 designated HVTN 56 Intervention Trial 56 Sibutramine Cardiovascular Outcomes 56 Phase IIA 56 ZD# [001] 56 efficacy 56 GetGoal Phase III 56 sipuleucel T 56 relapsing remitting multiple sclerosis 56 TASKi3 56 ACTEMRA TM 56 DEEP AF 56 ganetespib 56 gadobutrol 56 FFR guided treatment 56 vidofludimus 56 bronchial thermoplasty 56 rosuvastatin 56 Evaluation WISE 56 SYNERGY Stent 56 pegylated interferon alfa 2b 56 label multicenter randomized 56 zotarolimus eluting stent 56 Phase 2b clinical trials 56 iPrEx study 56 blind placebo 56 RoACTEMRA 56 Telmisartan 56 Trandolapril 56 XIENCE V PROMUS Stent 56 confirmatory Phase III 56 WHIMS 56 Elocalcitol 56 Zilver PTX 56 PICSO ® 56 fidaxomicin Phase 56 observational cohort 56 Androxal TM 56 interferon gamma 1b 56 DMIST 56 canakinumab 56 radiation dosimetry 56 RezularTM 56 strontium ranelate 56 NATRECOR R 56 PROSTVAC TM 56 eculizumab therapy 56 INCB# [001] 56 sirolimus eluting 56 Phase IIb 56 Dabigatran 56 RE LY trial 56 IMPACT IMmunotherapy 56 AA Amyloidosis 56 TAXUS Stent 56 PREZISTA r 56 Controlled Trial 56 CALERIE 56 Genous stent 56 ADHF 56 ENDEAVOR 56 confirmatory Phase 56 EMPHASIS HF trial 56 tolerability 56 reslizumab 56 neratinib 56 COPAXONE R 56 CHARISMA trial 56 Phase III randomized placebo 56 teriparatide 56 RADIANT 56 diabetic neuropathic pain 56 LITHE 56 CANCIDAS 56 TM Drug Eluting 56 postmenopausal women 56 Phase III multicenter 56 XIENCE V Stent System 56 CBLC# 56 ZoMaxx 56 Pivotal Phase III 56 metreleptin 56 Percutaneous Tibial Nerve Stimulation 56 relapsed refractory multiple myeloma 56 mg/m2 cohort 56 invasive candidiasis 56 II Clinical Trial 56 trastuzumab emtansine T DM1 56 trial evaluating PRX# 55 drug eluting stent DES 55 ORAL Sync 55 liver resection 55 fidaxomicin Phase 3 55 tipranavir 55 Feasibility Trial 55 Aflibercept 55 Phase IIa trials 55 forodesine 55 Ranolazine 55 eprotirome 55 MIRCERA 55 clinical endpoints 55 PROTECT AF 55 HIVNET 55 renal tumors 55 ISAR TEST 55 FDA Investigational Device 55 deferiprone 55 IMPACT DCM 55 Radiation Therapy Oncology 55 Ophena 55 Dose escalation 55 satraplatin Phase 55 randomized controlled trials RCTs 55 SIMPADICO 55 oral Xeloda 55 MoxDuo TM IR 55 unblinded 55 rosuvastatin #mg 55 Doxil ® 55 EVIZON 55 ZOLINZA 55 SYMMETRY trial 55 pharmacokinetic PK profile 55 PREVAIL 55 Placebo Controlled Trial 55 pivotal Phase 55 Phase 1b dose escalation 55 BST CarGel R 55 Phase III ThermoDox 55 PROTEGE 55 Patency 55 Xelox 55 TAXUS Liberte Long 55 COR Diabetes 55 bevacizumab Avastin 55 number NCT# ClinicalTrials.gov 55 Acute Decompensated Heart Failure 55 darunavir ritonavir 55 GRAVITAS trial 55 CLBP 55 AEGR 55 davunetide intranasal AL 55 Pharmacokinetic 55 pharmacodynamic 55 prospective longitudinal 55 ARCOXIA 55 RESOLUTE clinical 55 cluster randomized controlled 55 Phase III Clinical Trials 55 tocilizumab 55 CINQUIL 55 SORT OUT III 55 phase IIb III 55 duplex ultrasonography 55 Thrombolysis 55 Health Initiative WHI 55 NSTE ACS 55 Tocilizumab 55 investigational protease inhibitor 55 Relieve Depression STAR 55 ARBITER 6 55 multinational multicenter randomized 55 symptomatic BPH 55 aldosterone antagonists 55 Zenvia Phase III 55 multicenter randomized Phase 55 Randomized Double Blind Placebo 55 NCCTG N# 55 Valsartan 55 Natalizumab 55 Angiographic 55 secretin 55 STOP AF 55 meta analyzes 55 DU #b 55 LCP Tacro 55 noninferior 55 ERSPC 55 rALLy clinical trial 55 SPARCL 55 randomized #:# 55 F FDG PET 55 INCB# [003] 55 Infarct 55 safety tolerability pharmacokinetics 55 AZILECT R 55 FDG-PET/CT 55 Angiox R 55 doxorubicin docetaxel 55 Cloretazine 55 COSIRA trial 55 comparing XIENCE V 55 UKPDS 55 relapsed myeloma 55 Tumor Response 55 CRESTOR #mg 55 brivaracetam 55 AZILECT ® 55 AVANDIA 55 Zoraxel 55 Dialysis Outcomes 55 APTIVUS r 55 RIBBON 55 HYVET 55 Refractory Angina 55 Diabetic Macular Edema 55 ORMD 55 VICTOR E1 55 LCP AtorFen 55 CAPRIE 55 EFAPROXYN 55 observational studies 55 ascending dose study 55 dose regimens 55 recurrent glioma 55 PIX# [002] 55 posaconazole 55 SUTENT ® 55 ASPIRE HIGHER 55 Tolvaptan 55 ARIXTRA 55 dosing cohort 55 ZYBRESTAT fosbretabulin 55 CONQUER OB 55 dabigatran etexilate 55 #F FDG PET 55 ENGAGE AF TIMI 55 adjuvant colon cancer 55 docetaxel chemotherapy 55 IIa trial 55 dose proportionality 55 Cholesterol Levels SPARCL 55 unfractionated heparin UFH 55 observer blinded randomized 55 WallFlex Biliary RX 55 patients undergoing percutaneous 55 phase III SIMPADICO 55 Fondaparinux 55 Multi Ethnic Study 55 colorectal liver metastases 55 TAXUS stent 55 recurrent ovarian cancer 55 ARB telmisartan 55 rivaroxaban 55 MEND CABG II 55 rilonacept 55 Lipid Lowering Treatment 55 acute ischemic stroke 55 YONDELIS 55 controlled multicenter Phase 55 noninfectious uveitis 55 treatment naïve genotype 55 echocardiographic 55 stent DES 55 CALGB # [001] 55 catheter occlusion 54 mycophenolate mofetil 54 Tanespimycin 54 Phase 2b 54 Meta analyzes 54 Non inferiority 54 receptor tyrosine kinase inhibitor 54 IL# PE#QQR 54 Pertuzumab 54 QTinno 54 Randomized Controlled 54 Asthma Intervention 54 CombAT 54 QD dosing 54 EXPLORE Xa 54 selective androgen receptor modulator 54 Afatinib 54 Zemplar Capsules 54 relapsed AML 54 Deforolimus 54 chest radiographs 54 GLYX 54 factor Xa inhibitor 54 Denufosol 54 Sipuleucel T 54 pharmacodynamics 54 Antihypertensive 54 antihypertensive therapy 54 Dacogen injection 54 selenium supplementation 54 composite endpoint 54 dyskinesia PD LID 54 TLK# 54 bendamustine 54 COR Analyzer 54 pitavastatin 54 Phase 1b clinical trials 54 UPLIFT 54 arzoxifene 54 Taxus Stent 54 Xanafide 54 CYPHER R stent 54 Teriflunomide 54 POISE 54 lacosamide 54 antitumor effect 54 PD LID 54 IIa clinical 54 Diamyd r vaccine 54 PCPT 54 NCIC CTG 54 SNT MC# 54 Raptiva ® 54 efficacy endpoint 54 lomitapide 54 urodynamic 54 Phase IIB clinical 54 Phase IIb kidney transplant 54 adult chronic ITP 54 adalimumab 54 evaluating mipomersen 54 bowel resection 54 candesartan cilexetil 54 Eluting Coronary Stent System 54 XIENCE V demonstrated 54 metastatic hormone refractory 54 pharmacodynamic properties 54 oral diclofenac 54 telmisartan 54 QLT# 54 ORENCIA ® 54 tacrolimus ointment 54 Observational Study 54 AeroLEF TM 54 Clinical Study 54 elacytarabine 54 LibiGel Phase III 54 HIV HCV coinfected 54 clinical trials 54 refractory prostate cancer 54 STEALTH C 54 secondary endpoint 54 fenretinide 54 alvespimycin 54 APPROVe 54 sorafenib tablets 54 Cethromycin 54 iPrEx 54 antiepileptic drug 54 solithromycin 54 Ranibizumab 54 blind randomized multicenter 54 DCCT 54 EBUS FNA 54 XL# SAR# 54 CardioFit 54 Novo TTF 54 ENDEAVOR IV clinical 54 RESOLUTE 54 blind multicentre 54 neurologic progression 54 ACOSOG Z# 54 drug eluting coronary stent 54 Zilver PTX stent 54 retinal vein occlusion induced 54 cediranib 54 oral anticoagulant 54 Intravitreal 54 Bivalirudin 54 Carfilzomib 54 olaparib 54 EQUIP OB 54 OHR/AVR# 54 nesiritide 54 liver transplant recipients 54 Phase 2b dose 54 biliary tract cancer 54 neoadjuvant treatment 54 Phase III trials 54 APEX AMI trial 54 null responder HCV 54 multiple ascending dose 54 tesmilifene 54 Dr. Kandzari 54 Faslodex 54 Initiate Phase 54 Screening Trial DMIST 54 ponatinib 54 sunitinib 54 Tiotropium 54 pazopanib 54 Ceplene/IL-2 54 Phase III Trial 54 Left Ventricular Dysfunction 54 Heart Failure Therapies 54 factorial design 54 DEFER 54 Group RTOG 54 Drug Eluting Stents 54 plain radiographs 54 trodusquemine 54 Sym# 54 KRN# 54 efavirenz EFV 54 Randomized Phase III 54 multicenter clinical trials 54 HGS# 54 UPLYSO 54 Communities ARIC study 54 AZOR 54 epidemiologic studies 54 Phase IIb trials 54 retinal thickness 54 percutaneous vertebroplasty 54 irbesartan 54 Zarnestra 54 Women Ischemia Syndrome 54 Cellulaze 54 farletuzumab 54 MIVI TRUST 54 concurrent chemoradiation 54 TAXUS Express Stent 54 OPCAB 54 trabedersen 54 CTRC AACR San Antonio 54 relapsed multiple myeloma 54 dose cohort 54 angiographic outcomes 54 lipid lowering therapy 54 ISEL 54 pegylated liposomal doxorubicin 54 Alemtuzumab 54 chemotherapy gemcitabine 54 Enzastaurin 54 elotuzumab 54 Controlled Study 54 cangrelor 54 Solorel 54 SCH # 54 interferon beta therapy 54 induced macular edema 54 Monitoring ABPM 54 tremelimumab 54 clopidogrel Plavix 54 Combination REOLYSIN R 54 Multimeric 54 subtrochanteric 54 iniparib 54 dose cohorts 54 Quinamed 54 Stedivaze 54 standard chemotherapy regimen 54 AREDS 54 thromboprophylaxis 54 bolus dose 54 IMA# 54 patients undergoing CABG 54 intravenous bisphosphonates 54 Daclizumab 54 Primary endpoints 54 GSK# [001] 54 ID NCT# 54 somatostatin analog 54 visilizumab 54 JAK inhibitor

Back to home page